APTOF

Aptose Biosciences Inc.

Price Chart

Latest Quote

$1.58

+0.00 (+0.00%)

Current Price

Previous Close	$1.58
Open	$1.58
Day High	$1.58
Day Low	$1.58
Volume	15

Fetched: 2026-06-04T12:20:40

Stock Information

Shares Outstanding	2.55M
Total Debt	$32.95M
Cash Equivalents	$1.02M
Net Income	$-27.56M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$4.03M
EPS (TTM)	$-10.41
Exchange	OQB

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$35.96M
Income	$-27.56M
Book/sh	$-13.58
Cash/sh	$0.40
Employees	14

Financial Ratios

Quick Ratio	0.09
Current Ratio	0.55

Returns & Margins

ROA

-181.72%

Ownership

Insider Ownership	27.37%
Institutional Ownership	3.91%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-2.36
PEG	1.13
P/B	-0.12

Analyst Data

Recommendation

none

Technical Indicators

SMA20	$1.68
SMA50	$1.69
SMA200	$1.51
RSI	35.00
ATR	0.0314

Shares Float	1.86M
Short Float	2.60%
Short Ratio	0.14

Performance History

Week	-5.95%
Month	-7.06%
Quarter	+0.64%
6 Months	-4.24%
YTD	+2.60%
Year	-8.14%
3 Years	-99.16%
5 Years	-99.93%
10 Years	-99.87%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-03	$1.58	0
2026-06-02	$1.58	1,100
2026-06-01	$1.68	300
2026-05-29	$1.65	900
2026-05-28	$1.57	400
2026-05-27	$1.68	500
2026-05-26	$1.70	700
2026-05-22	$1.70	2,700
2026-05-21	$1.71	100
2026-05-20	$1.69	3,000
2026-05-19	$1.69	2,700
2026-05-18	$1.70	0
2026-05-15	$1.70	10,400
2026-05-14	$1.71	300
2026-05-13	$1.70	700
2026-05-12	$1.71	0
2026-05-11	$1.71	1,700
2026-05-08	$1.68	1,400
2026-05-07	$1.68	200
2026-05-06	$1.72	300
2026-05-05	$1.72	600
2026-05-04	$1.70	1,700

About Aptose Biosciences Inc.

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops precision medicines addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes. It has license agreements with National Cancer Institute for the clinical development of tuspetinib; and Hanmi Pharmaceutical Co Ltd. to research, develop, and commercialize tuspetinib. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.

📰 Latest News

Aptose Biosciences: Q3 Earnings Snapshot

Associated Press Finance • 2025-11-13T22:17:35Z

Aptose Biosciences Reports Promising Early Results from Tuscany AML Trial of Tuspetinib Combo Therapy

MT Newswires • 2025-10-16T12:36:34Z

Aptose Secures US$11.9M Loan Extension to Advance Tuspetinib AML Trial

MT Newswires • 2025-09-22T12:09:50Z

Aptose Biosciences Reports Early Positive Tuspetinib Safety Data Across Newly Diagnosed AML Patients

MT Newswires • 2025-08-18T12:01:51Z

Aptose Biosciences: Q2 Earnings Snapshot

Associated Press Finance • 2025-08-13T20:41:57Z

Aptose Biosciences Moves to Higher Dose in Phase 1/2 Cancer Study After Positive Safety Review

MT Newswires • 2025-08-06T20:52:39Z

Period:

Income Statement (Annual)

Metric	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Revenue
Total Revenue	$0	$0	$0	$0
Operating Revenue	$0	$0	$0	$0
Expenses
Interest Expense	$207,000	$0	-	-
Total Expenses	$26,257,000	$52,356,000	$42,602,000	$65,447,000
Other Income Expense	$677,000	$-2,000	$-9,000	$-1,000
Net Non Operating Interest Income Expense	$150,000	$1,151,000	$788,000	$94,000
Interest Expense Non Operating	$207,000	$0	-	-
Operating Expense	$26,257,000	$52,356,000	$42,602,000	$65,447,000
General And Administrative Expense	$11,135,000	$15,542,000	$14,433,000	$19,324,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-25,430,000	$-51,207,000	$-41,823,000	$-65,354,000
Net Interest Income	$150,000	$1,151,000	$788,000	$94,000
Interest Income	$357,000	$1,151,000	$788,000	$94,000
Normalized Income	$-26,107,000	$-51,205,000	$-41,814,000	$-65,353,000
Net Income From Continuing And Discontinued Operation	$-25,430,000	$-51,207,000	$-41,823,000	$-65,354,000
Net Income Common Stockholders	$-25,430,000	$-51,207,000	$-41,823,000	$-65,354,000
Net Income	$-25,430,000	$-51,207,000	$-41,823,000	$-65,354,000
Net Income Including Noncontrolling Interests	$-25,430,000	$-51,207,000	$-41,823,000	$-65,354,000
Net Income Continuous Operations	$-25,430,000	$-51,207,000	$-41,823,000	$-65,354,000
Pretax Income	$-25,430,000	$-51,207,000	$-41,823,000	$-65,354,000
Interest Income Non Operating	$357,000	$1,151,000	$788,000	$94,000
Operating Income	$-26,257,000	$-52,356,000	$-42,602,000	$-65,447,000
Depreciation Amortization Depletion Income Statement	$19,000	$49,000	$81,000	$138,000
Depreciation And Amortization In Income Statement	$19,000	$49,000	$81,000	$138,000
Depreciation Income Statement	$19,000	$49,000	$81,000	$138,000
Per Share
Diluted EPS	$-36.38	$-227.43	$-204.00	$-328.50
Basic EPS	$-36.38	$-227.43	$-204.00	$-328.50
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-25,496,000	$-50,739,000	$-42,065,000	$-64,824,000
Total Unusual Items	$677,000	$-2,000	$-9,000	$-1,000
Total Unusual Items Excluding Goodwill	$677,000	$-2,000	$-9,000	$-1,000
Reconciled Depreciation	$404,000	$466,000	$528,000	$622,000
EBITDA (Bullshit earnings)	$-24,819,000	$-50,741,000	$-42,074,000	$-64,825,000
EBIT	$-25,223,000	$-51,207,000	$-42,602,000	$-65,447,000
Diluted Average Shares	$698,979	$225,154	$205,033	$197,968
Basic Average Shares	$698,979	$225,154	$205,033	$197,968
Diluted NI Availto Com Stockholders	$-25,430,000	$-51,207,000	$-41,823,000	$-65,354,000
Gain On Sale Of Security	$677,000	$-2,000	$-9,000	$-1,000
Research And Development	$15,103,000	$36,765,000	$28,088,000	$45,985,000
Selling General And Administration	$11,135,000	$15,542,000	$14,433,000	$19,324,000
Other Gand A	$10,421,000	$13,262,000	$11,444,000	$10,164,000
Salaries And Wages	$714,000	$2,280,000	$2,989,000	$9,160,000

Fetched: 2026-02-02

Balance Sheet (Annual)

Metric	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Assets
Net Tangible Assets	$-4,543,000	$-2,901,000	$37,741,000	$74,236,000
Total Assets	$10,127,000	$12,989,000	$51,027,000	$82,525,000
Total Non Current Assets	$597,000	$1,095,000	$1,508,000	$788,000
Current Assets	$9,530,000	$11,894,000	$49,519,000	$81,737,000
Other Current Assets	$570,000	$600,000	$257,000	$133,000
Restricted Cash	$555,000	$0	-	-
Prepaid Assets	$2,253,000	$2,042,000	$2,303,000	$2,476,000
Cash Cash Equivalents And Short Term Investments	$6,152,000	$9,252,000	$46,959,000	$79,128,000
Cash And Cash Equivalents	$6,152,000	$9,252,000	$36,970,000	$39,114,000
Cash Equivalents	$4,646,000	$6,488,000	$36,374,000	$38,820,000
Cash Financial	$1,506,000	$2,764,000	$596,000	$294,000
Debt
Net Debt	$3,866,000	-	-	-
Total Debt	$10,639,000	$1,015,000	$1,303,000	$574,000
Long Term Debt And Capital Lease Obligation	$10,211,000	$621,000	$1,002,000	$115,000
Long Term Debt	$10,018,000	-	-	-
Current Debt And Capital Lease Obligation	$428,000	$394,000	$301,000	$459,000
Liabilities
Total Liabilities Net Minority Interest	$14,670,000	$15,890,000	$13,286,000	$8,289,000
Total Non Current Liabilities Net Minority Interest	$10,211,000	$621,000	$1,002,000	$115,000
Current Liabilities	$4,459,000	$15,269,000	$12,284,000	$8,174,000
Payables And Accrued Expenses	$4,031,000	$14,875,000	$11,983,000	$7,715,000
Payables	$1,258,000	$6,046,000	$6,326,000	$1,699,000
Accounts Payable	$1,258,000	$3,492,000	$3,342,000	$1,699,000
Equity
Common Stock Equity	$-4,543,000	$-2,901,000	$37,741,000	$74,236,000
Total Equity Gross Minority Interest	$-4,543,000	$-2,901,000	$37,741,000	$74,236,000
Stockholders Equity	$-4,543,000	$-2,901,000	$37,741,000	$74,236,000
Gains Losses Not Affecting Retained Earnings	$-4,316,000	$-4,316,000	$-4,318,000	$-4,316,000
Other Equity Adjustments	$-4,316,000	$-4,316,000	$-4,318,000	$-4,316,000
Retained Earnings	$-540,967,000	$-515,537,000	$-464,330,000	$-422,507,000
Other
Ordinary Shares Number	$2,006,027	$264,745	$205,260	$204,922
Share Issued	$2,006,027	$264,745	$205,260	$204,922
Tangible Book Value	$-4,543,000	$-2,901,000	$37,741,000	$74,236,000
Invested Capital	$5,475,000	$-2,901,000	$37,741,000	$74,236,000
Working Capital	$5,071,000	$-3,375,000	$37,235,000	$73,563,000
Capital Lease Obligations	$621,000	$1,015,000	$1,303,000	$574,000
Total Capitalization	$5,475,000	$-2,901,000	$37,741,000	$74,236,000
Additional Paid In Capital	$83,336,000	$72,146,000	$68,869,000	$63,673,000
Capital Stock	$457,404,000	$444,806,000	$437,520,000	$437,386,000
Common Stock	$457,404,000	$444,806,000	$437,520,000	$437,386,000
Long Term Capital Lease Obligation	$193,000	$621,000	$1,002,000	$115,000
Current Capital Lease Obligation	$428,000	$394,000	$301,000	$459,000
Current Accrued Expenses	$2,773,000	$8,829,000	$5,657,000	$6,016,000
Dueto Related Parties Current	$0	$2,554,000	$2,984,000	-
Net PPE	$597,000	$1,095,000	$1,508,000	$788,000
Accumulated Depreciation	$-3,071,000	$-2,830,000	$-2,533,000	$-2,185,000
Gross PPE	$3,668,000	$3,925,000	$4,041,000	$2,973,000
Leases	$171,000	$213,000	$184,000	$184,000
Other Properties	$3,124,000	$3,321,000	$3,297,000	$2,229,000
Machinery Furniture Equipment	$373,000	$391,000	$560,000	$560,000
Properties	$0	$0	$0	$0
Treasury Shares Number	-	$0	-	-
Other Short Term Investments	-	$0	$9,989,000	$40,014,000

Fetched: 2026-02-02

Cash Flow Statement (Annual)

Metric	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Free Cash Flow
Free Cash Flow	$-35,982,000	$-44,619,000	$-32,346,000	$-43,516,000
Operating Activities
Operating Cash Flow	$-35,977,000	$-44,590,000	$-32,322,000	$-43,304,000
Cash Flow From Continuing Operating Activities	$-35,977,000	$-44,590,000	$-32,322,000	$-43,304,000
Operating Gains Losses	$-610,000	-	$20,000	$-7,000
Investing Activities
Capital Expenditure	$-5,000	$-29,000	$-24,000	$-212,000
Investing Cash Flow	$18,000	$9,960,000	$30,066,000	$-35,208,000
Cash Flow From Continuing Investing Activities	$18,000	$9,960,000	$30,066,000	$-35,208,000
Financing Activities
Repurchase Of Capital Stock	$-21,000	-	-	-
Issuance Of Capital Stock	$23,407,000	$6,881,000	$101,000	$36,000
Financing Cash Flow	$33,414,000	$6,910,000	$116,000	$226,000
Cash Flow From Continuing Financing Activities	$33,414,000	$6,910,000	$116,000	$226,000
Net Common Stock Issuance	$23,386,000	$6,881,000	$101,000	$36,000
Common Stock Issuance	$23,407,000	$6,881,000	$101,000	$36,000
Other
Issuance Of Debt	$10,000,000	$0	-	-
End Cash Position	$6,707,000	$9,252,000	$36,970,000	$39,114,000
Beginning Cash Position	$9,252,000	$36,970,000	$39,114,000	$117,393,000
Effect Of Exchange Rate Changes	$0	$2,000	$-4,000	$7,000
Changes In Cash	$-2,545,000	$-27,720,000	$-2,140,000	$-78,286,000
Proceeds From Stock Option Exercised	$28,000	$29,000	$15,000	$190,000
Common Stock Payments	$-21,000	-	-	-
Net Issuance Payments Of Debt	$10,000,000	$0	-	-
Net Long Term Debt Issuance	$10,000,000	$0	-	-
Long Term Debt Issuance	$10,000,000	$0	-	-
Net Investment Purchase And Sale	$0	$9,989,000	$30,090,000	$-34,996,000
Sale Of Investment	$0	$9,989,000	-	-
Net PPE Purchase And Sale	$18,000	$-29,000	$-24,000	$-212,000
Sale Of PPE	$23,000	$0	-	-
Purchase Of PPE	$-5,000	$-29,000	$-24,000	$-212,000
Change In Working Capital	$-11,025,000	$2,810,000	$4,317,000	$1,516,000
Change In Other Current Assets	$30,000	$-343,000	$-124,000	$-4,000
Change In Payables And Accrued Expense	$-10,844,000	$2,892,000	$4,268,000	$1,442,000
Change In Accrued Expense	$-6,056,000	$3,172,000	$-3,343,000	$1,914,000
Change In Payable	$-4,788,000	$-280,000	$7,611,000	$-472,000
Change In Account Payable	$-4,788,000	$-280,000	$7,611,000	$-472,000
Change In Prepaid Assets	$-211,000	$261,000	$173,000	$78,000
Other Non Cash Items	$-376,000	$-312,000	$-571,000	$6,970,000
Stock Based Compensation	$1,060,000	$3,653,000	$5,207,000	$12,949,000
Depreciation Amortization Depletion	$404,000	$466,000	$528,000	$622,000
Depreciation And Amortization	$404,000	$466,000	$528,000	$622,000
Depreciation	$404,000	$466,000	$528,000	$622,000
Gain Loss On Investment Securities	$-686,000	-	-	-
Gain Loss On Sale Of PPE	$76,000	$0	$16,000	$0
Net Income From Continuing Operations	$-25,430,000	$-51,207,000	$-41,823,000	$-65,354,000
Net Foreign Currency Exchange Gain Loss	-	$0	$4,000	$-7,000
Purchase Of Investment	-	-	-	$-34,996,000

Fetched: 2026-02-02